Developmental Dieldrin Exposure Alters DNA Methylation at Genes Related to Dopaminergic Neuron Development and Parkinson's Disease in Mouse Midbrain

Joseph Kochmanski, Sarah E. VanOeveren, Joseph R. Patterson, and Alison I. Bernstein¹

Department of Translational Science & Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503

¹To whom correspondence should be addressed at Department of Translational Science & Molecular Medicine, College of Human Medicine, Michigan State University, 400 Monroe Ave NW, Grand Rapids, MI 49503. E-mail: Alison.Bernstein@hc.msu.edu.

ABSTRACT

Human and animal studies have shown that exposure to the organochlorine pesticide dieldrin is associated with increased risk of Parkinson's disease (PD). Despite previous work showing a link between developmental dieldrin exposure and increased neuronal susceptibility to MPTP toxicity in male C57BL/6 mice, the mechanism mediating this effect has not been identified. Here, we tested the hypothesis that developmental exposure to dieldrin increases neuronal susceptibility via genome-wide changes in DNA methylation. Starting at 8 weeks of age and prior to mating, female C57BL/6 mice were exposed to 0.3 mg/kg dieldrin by feeding (every 3 days) throughout breeding, gestation, and lactation. At 12 weeks of age, pups were sacrificed and ventral mesencephalon, containing primarily substantia nigra, was microdissected. DNA was isolated and dieldrin-related changes in DNA methylation were assessed via reduced representation bisulfite sequencing. We identified significant, sex-specific differentially methylated CpGs (DMCs) and regions (DMRs) by developmental dieldrin exposure (false discovery rate < 0.05), including DMCs at the *Nr4a2* and *Lmx1b* genes, which are involved in dopaminergic neuron development and maintenance. Developmental dieldrin exposure had distinct effects on the male and female epigenome. Together, our data suggest that developmental dieldrin exposure establishes sex-specific poised epigenetic states early in life. These poised epigenomes may mediate sensitivity to subsequent toxic stimuli and contribute to the development of late-life neurodegenerative disease, including PD.

Key words: dieldrin; pesticides; DNA methylation; epigenetics; Parkinson's disease; RNA-sequencing.

Parkinson's disease (PD), the most common neurodegenerative movement disorder, is characterized by formation of α -synuclein-containing Lewy bodies and progressive degeneration of dopaminergic neurons of the nigrostriatal pathway (Fahn, 2003). Previous research has estimated that only 5%–10% of PD cases are familial (caused by monogenic mutations), whereas the remaining 90%–95% of cases are sporadic (Lill, 2016; Trinh and Farrer, 2013). Although the etiology of sporadic PD remains unclear, studies suggest it may involve an interaction between

genetics and environment (Cannon and Greenamyre, 2013; Fleming, 2017; Lill, 2016). Supporting this idea, both human and animal studies have shown that exposure to certain classes of environmental toxicants, including specific types of industrial toxicants and pesticides, is associated with increased risk of PD (Caudle et al., 2012; Cicchetti et al., 2009; Freire and Koifman, 2012; Goldman et al., 2017; Moretto and Colosio, 2011).

Dieldrin is a highly toxic organochlorine pesticide that was phased out of commercial use in the 1970s, but has persisted in

the environment due to its high stability and lipophilicity (CDC, 2016). Given these properties, dieldrin accumulates in lipid-rich tissues like the brain, and has been classified as a persistent organic pollutant (Corrigan et al., 2000; Jorgenson, 2001; Kanthasamy et al., 2005). Previous epidemiology studies have shown a positive association between dieldrin exposure and PD risk (Kanthasamy et al., 2005; Moretto and Colosio, 2011), and mechanistic animal research has shown that adult and developmental dieldrin exposures are associated with oxidative stress and disrupted expression of PD-related proteins (Hatcher et al., 2007; Richardson et al., 2006). In particular, male and female mice developmentally exposed to dieldrin showed increased dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) protein levels, as well as increased *Nr4a2* expression (Richardson et al., 2006). In male mice only, developmental exposure to dieldrin led to an increased DAT:VMAT2 ratio and exacerbated MPTP neurotoxicity (Richardson et al., 2006). Vesicular integrity, and specifically the DAT:VMAT2 ratio, can impact vulnerability of dopaminergic neurons to neurotoxicants (Alter et al., 2013; Miller et al., 1999), and this ratio has been used to predict susceptibility of neurons to PD-related neurodegeneration (Uhl, 1998). However, the biological mechanism mediating these long-lasting effects of developmental dieldrin exposure on the dopaminergic system has not been identified.

The epigenome is recognized as a potential mediator of the relationship between developmental exposures and adult disease. Epigenetic marks are sensitive to the environment, established during cellular differentiation, and regulate gene expression throughout the lifespan (Allis and Jenuwein, 2016; Faulk and Dolinoy, 2011). Thus, it is possible that developmental dieldrin exposure induces fixed changes in the epigenome, creating a poised epigenetic state in which developmental exposure has programmed a modified response to later-life challenges. In addition, evidence for epigenetic regulation playing a role in PD has been growing, particularly for DNA methylation (Cheng et al., 2015; Jakovcevski and Akbarian, 2012; Labbé et al., 2016; Lardenoije et al., 2018; Marques and Outeiro, 2013; Miranda-Morales et al., 2017; Wüllner et al., 2016).

Based on the documented link between developmental dieldrin and adult susceptibility to neurodegeneration, we hypothesized that developmental dieldrin exposure leads to genome-wide changes in epigenetic regulation. To test this hypothesis, we characterized genome-wide DNA methylation and the transcriptome in animals developmentally exposed to dieldrin.

MATERIALS AND METHODS

Animals. Male and female C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, Maine). Female mice were 7 weeks old upon arrival and were allowed to habituate for 1 week prior to the start of the developmental dieldrin exposure study. In contrast, male mice used for breeding in the developmental exposure study were 8–12 weeks old upon arrival. In the adult exposure study, male mice were 7 weeks old upon arrival and were allowed to habituate for 1 week prior to the start of dieldrin exposure. Mice were maintained on a 12:12 reverse light/dark cycle. Mice were housed in Thoren ventilated caging systems with automatic water and 1/8-inch Bed-O-Cobs bedding with Enviro-Dri for enrichment. Food and water were available *ad libitum*. Mice were maintained on standard LabDiet 5021 chow (LabDiet, St Louis, Missouri). F0 females were individually housed during dieldrin dosing, except during the mating phase. F1 pups were group housed by sex; no more than 4 animals were housed per cage. All procedures were conducted in

accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Michigan State University.

Dieldrin exposure paradigm. For both adult and developmental exposure, mice were administered 0.3 mg/kg dieldrin dissolved in corn oil vehicle and mixed with peanut butter pellets every 3 days (Gonzales et al., 2014). Control mice received an equivalent amount of corn oil vehicle in peanut butter. This dose was used based on previous results showing low toxicity, but clear developmental effects (Richardson et al., 2006). Consumption of peanut butter pellets was ensured via visual inspection and typically occurred within minutes.

In the developmental exposure study, adult C57BL/6 (8-week-old) female animals were treated throughout breeding, gestation, and lactation (Figure 1A). Four weeks into female exposure, unexposed C57BL/6 males (8–12 weeks old) were introduced for breeding. Offspring were weaned at 3 weeks of age and separated by litter and by sex. At 12 weeks of age, male and female offspring from independent litters were sacrificed and ventral mesencephalon was dissected. This time point was chosen based on previous results demonstrating increased neuronal susceptibility to MPTP at 12 weeks of age (Richardson et al., 2006). Two male and 2 female littermates from independent litters were chosen for RNA and DNA isolation ($n = 6$ per treatment per sex per outcome) (Supplementary Table 1).

In the adult exposure study, 8-week-old C57BL/6 male animals were fed dieldrin (0.3 mg/kg) by the same method every 3 days for 30 days. After the 30-day exposure period, mice were sacrificed and midbrain samples were collected. Midbrains from both the control ($n = 5$) and dieldrin-exposed mice ($n = 5$) were selected for DNA isolation follow-up.

Ventral mesencephalon dissection. Upon sacrifice by cervical dislocation, the ventral mesencephalon, which contains primarily the substantia nigra (SN), was dissected using techniques based on previously described methods (Salvatore et al., 2012). Briefly, whole brains were rinsed with ddH₂O to remove any blood or hair and placed in a pre-chilled brain matrix. Razor blades were placed immediately caudal of the third ventricle and 1 mm caudal of the first blade. This coronal section containing the SN was transferred to a chilled metal stage. On the chilled stage, cortex and hippocampus were removed, and the SN was microdissected to remove the ventral tegmental area and the medial lemniscus (Supplementary Figure 1).

DNA and RNA isolations. DNA isolation was performed using the phenol:chloroform:isoamyl alcohol method. Briefly, 20 μ l proteinase K (Qiagen, Hilden, Germany) and 180 μ l ATL lysis buffer (Qiagen) were added to each midbrain tissue sample in a 1.5 ml microcentrifuge tube. A Kimble Kontes pellet pestle (Kimble Chase, Rockwood, Tennessee) was then used to grind the tissue. After vortexing, samples were allowed to digest for 3 h in a ThermoMixer set at 55°C, 300 rpm. Lysed samples were then centrifuged for 1 min at 12 000 $\times$ g and the supernatant was transferred to a new 1.5 ml tube. To ensure RNA-free genomic DNA isolation, 4 μ l RNase A (100 mg/ml) (Qiagen) was added to each supernatant; samples were then mixed by vortexing and incubated at room temperature for 2 min. An equal volume of phenol:chloroform:isoamyl alcohol (ThermoFisher, Waltham, Massachusetts) was then added to each supernatant. Samples were mixed by inverting for approximately 20 s, and then centrifuged at room temperature for 5 min at 16 000 $\times$ g. The top

Figure 1. Developmental exposure paradigm and timeline. A, Adult C57BL/6 (8-week-old) female animals were treated with dieldrin (0.3 mg/kg, every 3 days) or vehicle control during the entire developmental period. Dietary dieldrin was fed orally using a mixture of corn oil and peanut butter throughout breeding, gestation, and lactation. Vehicle control mice were fed peanut butter with corn oil only. Four weeks into female exposure, males were introduced for breeding. Offspring were weaned at 3 weeks of age, at which point they were separated by litter and by sex. After developmental exposure, male and female offspring (F1) were raised on control diet and followed to adulthood. B, At 12 weeks of age, F1 offspring were sacrificed, bilateral midbrain samples were dissected, and DNA and RNA were isolated from paired littermates. The transcriptome was assessed from RNA samples using RNA-sequencing technology and genome-wide DNA methylation was assessed by reduced representation bisulfite sequencing. C, Genome-wide DNA methylation was measured from isolated DNA to identify specific cytosine-phospho-guanine (CpG) sites that showed differential DNA methylation by developmental dieldrin exposure.

aqueous phase (containing DNA) was then transferred to a new 1.5 ml microcentrifuge tube. To precipitate DNA, 7.5 M ammonium acetate (Sigma-Aldrich, St Louis, Missouri) and 100% ethanol (Decon Labs Inc., King of Prussia, Pennsylvania) were added at 0.5× and 2.5× the sample volume, respectively. Tubes were then placed in -80°C freezer for 2 h to precipitate DNA. After thawing samples, DNA was pelleted by centrifugation at 4°C for 30 min at $16\,000 \times g$. After removing supernatant, the DNA pellet was washed by adding 150 μl 70% ethanol, and then centrifuging at 4°C for 2 min at $16\,000 \times g$. After repeating this wash step once more, dry pellets were centrifuged again at 4°C for 1 min at $16\,000 \times g$. Excess 70% ethanol was removed, and tubes were inverted on the benchtop for 5 min or until pellets were dry. DNA pellet was then resuspended in 50 μl 10 mM UltraPure Tris pH 8.0 (ThermoFisher). DNA yield was determined using a Qubit 3 fluorometer (ThermoFisher), and DNA purity was assessed using a Take3 plate micro-volume plate on a BioTek Synergy H1 (BioTek Instruments, Inc., Winooski, Vermont). Isolated DNA was stored at -80°C .

RNA isolation was performed using a modified RNeasy Lipid Tissue Mini Kit (Qiagen). Several changes were made to the standard RNeasy Lipid Tissue Mini kit to improve RNA yield from midbrain samples. First, tissue was homogenized in 200 μl cold Qiazol lysis reagent using a Kimble Kontes pellet pestle for microcentrifuge tubes. Second, after physical homogenization, an additional 800 μl of Qiazol lysis reagent was added to each tissue sample. Third, after initial centrifugation, supernatant was transferred to an Invitrogen Phasemaker tube (ThermoFisher) to facilitate transfer of the RNA-containing aqueous layer. As a result of using the Phasemaker tubes, the second centrifugation step was reduced from 15 to 5 min. In

addition to these changes, the optional DNase digestion step (as detailed in RNeasy Lipid Tissue Kit Protocol) was included to improve purity of isolated RNA. RNA was eluted in 50 μl RNase-free water, and RNA yield and purity were both assessed using the Agilent RNA 6000 Pico Reagents with the Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa Clara, California). Isolated RNA was stored at -80°C .

Reduced representation bisulfite sequencing. Genome-wide DNA methylation levels were measured using reduced representation bisulfite sequencing (RRBS) (Gu et al., 2010). Reduced representation bisulfite sequencing is a genome-wide sequencing method that utilizes a restriction enzyme (*MspI*) to specifically cut at CCGG nucleotide sequences, thereby enriching for cytosine-phospho-guanine (CpG)-dense regions. Reduced representation bisulfite sequencing library preparation was performed at the University of Michigan Epigenomics Core. Briefly, 200 ng of genomic DNA was digested for 16–8 h using *MspI*, a restriction enzyme that preferentially cuts DNA at CCGG nucleotide sequences. Restriction enzyme-digested DNA was purified using phenol:chloroform extraction and ethanol precipitation in the presence of glycogen and sodium acetate. Precipitated DNA was resuspended in 10 mM Tris-Cl pH 8.5 and processed for end-repair, A-tailing, and ligation of adapters with methylated cytosines. The ligated DNA was further cleaned according to the NuGEN TrueMethyl oxBS module (NuGEN, Redwood City, California; Cat No. 0414-32) instructions with 80% acetonitrile and magnetic beads. Ligated DNA was then eluted in UltraPure water and split into 2 tubes, one processed for bisulfite conversion only and the other processed for oxidative-bisulfite treatment, according to the TrueMethyl kit's instructions. After

bisulfite conversion and cleanup, the samples were amplified using the Roche High Fidelity FastStart system (Sigma-Aldrich) and TruSeq PCR primers (Illumina Inc., San Diego, California), according to the following protocol: 94°C for 5 min; 18 cycles of 94°C for 20 s, 65°C for 30 s, and 72°C for 1 min; 72°C for 3 min. Final library cleanup was done with 1:1 volume of Agencourt AMPure XP SPRI beads (Beckman Coulter, Brea, California). Each library was eluted into 20 µl of 10 mM Tris-HCl pH 8.5. Libraries were quantified using the Qubit dsDNA High Sensitivity kit (ThermoFisher), and library quality was assessed with the Agilent High Sensitivity D1000 ScreenTape assay (Agilent Technologies). Sequencing of RRBS libraries was performed at the Van Andel Genomics Core. To minimize batch effects, individually indexed libraries were randomized and pooled into 2 groups. Paired-end, 75 bp sequencing was performed on an Illumina NovaSeq6000 sequencer using 200 bp S1 sequencing kits (Illumina Inc.). Reduced representation bisulfite sequencing data had genomic coverage of approximately 3 000 000 CpG sites for each sample.

RNA-sequencing. Whole-genome RNA transcript expression was measured using RNA-sequencing (RNA-seq) (Wang et al., 2009). RNA-seq library preparation was performed at the Van Andel Genomics Core. Libraries were prepared from 100 ng of total RNA using the KAPA RNA HyperPrep Kit with RiboseErase (v1.16) (Kapa Biosystems, Wilmington, Massachusetts). As part of the library prep, RNA was sheared to 300–400 bp. After cDNA synthesis, but prior to PCR amplification, cDNA fragments were ligated to Bioo Scientific NEXTflex Adapters (Bioo Scientific, Austin, Texas). Library quality and quantity was assessed using a combination of Agilent DNA High Sensitivity chip (Agilent Technologies, Inc.), Quantifluor dsDNA System (Promega Corp, Madison, Wisconsin), and Kapa Illumina Library Quantification qPCR assays (Kapa Biosystems). Individually indexed libraries were randomized and pooled to minimize batch effects. Paired-end, 75 bp sequencing was performed on an Illumina NextSeq 500 sequencer using a 150 bp HO sequencing kit (v2) (Illumina Inc.). All libraries were run across 3 flowcells to achieve a minimum read depth of 60 M read pairs per library.

Sequencing QC and adapter trimming. Bioinformatics pipelines are outlined in Figure 2. Linux command line tools and the open-source statistical software R (version 3.5.1) were used for all analyses. For all sequencing data, the FastQC tool (version 0.11.5) was used for data quality control, and the *trim_galore* tool (version 0.4.5) was used for adapter trimming (Andrews, 2016; Krueger, 2017). During adapter trimming, we used the default minimum quality score and added a stringency value of 6, thereby requiring a minimum overlap of 6 bp. For the RRBS data, reads were trimmed in “RRBS mode” using the *rrbs* parameter; this parameter was not included for RNA-seq data trimming.

Differential methylation analysis. Trimmed RRBS reads were aligned to the mm10 genome using *bismark* (version 0.19.1) and *boutie2* (version 2.3.2) with default parameters (Krueger, 2018; Langmead, 2017). Methylation data were extracted from the aligned reads in *bismark* using a minimum threshold of 5 reads to include a CpG site in analysis.

The DSS (version 2.30.0) and *DMRcate* (version 1.18.0) R packages were used in parallel to test RRBS data for differential methylation by dieldrin exposure (Feng et al., 2014; Peters et al., 2015). Given that dieldrin exposure has shown sex-specific effects on the dopaminergic phenotype (Richardson et al., 2006), all differential methylation models were stratified by sex.

All pups included in modeling were from independent litters (Supplementary Table 1). To test for differentially methylated CpGs (DMCs) by dieldrin exposure, we used the *DMLtest* function in DSS to perform 2-group Wald tests. For *DMLtest* modeling, the equal dispersion and smoothing parameters were set to false. Differentially methylated CpGs significance was determined using a false discovery rate (FDR) cutoff < 0.05. To test for differentially methylated regions (DMRs), we combined outputs from the *callDMR* function in DSS and the *dmrcate* function in *DMRcate*. For *callDMR* modeling, the *p*-value threshold was set to .05, minimum length was set to 20 base pairs, and minimum CpGs was set to 3. Meanwhile, for *dmrcate* modeling, the lambda value was set to 500, the C value was set to 4, and minimum CpGs was set to 3. Within the *dmrcate* function, groups of DSS-derived FDRs for individual CpG sites are Stouffer transformed; here, DMR significance for the *dmrcate* output was set to Stouffer value < 0.10.

After differential methylation testing, the *annotatr* R package (version 1.8.0) was used to annotate identified DMCs and DMRs to the reference mm10 genome (Cavalcante and Sartor, 2017). Within *annotatr*, the *annotate_regions* function was used to generate CpG category, gene body, and regulatory feature annotations. To provide a more complete annotation, custom miRNA (sourced from: <http://www.mirbase.org/ftp.shtml>; last accessed March 21, 2019) and ENCODE predicted mouse midbrain enhancer (sourced from: <https://www.encodeproject.org/annotations/ENCSCR114ZIJ/>; last accessed March 21, 2019) databases were added to the annotation cache in *annotatr*. Distributions of DMCs by genomic annotation were plotted using the *plot_annotation* function in *annotatr* (Supplementary Figure 2). Overlap between male- and female-specific DMCs and DMRs was tested using the *bedtools* (version 2.27.1) *intersect* function (Quinlan and Kindlon, 2017).

Differential expression analysis. Following adapter trimming, read counts were quantified and quasi-mapped to a self-generated mm10 index using the *salmon* tool (version 0.11.3) (Patro et al., 2017). During read quantification in *salmon*, the *numBootstraps* parameter was used to generate 100 bootstraps for each sample. Quantified RNA-seq reads were then processed for downstream analyses using the *prepare_fish_for_sleuth* function in the *wasabi* R package (version 0.3) (Patro, 2018).

The *sleuth* R package (version 0.30.0) was used to test *wasabi*-processed RNA-seq data for differential transcript expression (DTE) by dieldrin exposure (Pimentel et al., 2017). Matching the DNA methylation analysis pipeline, all DTE models were stratified by sex. Prior to analysis, the Ensembl mouse transcript annotation database was read into R using the *biomaRt* package. Additionally, to limit analyses to high-quality data, only transcripts with greater than 10 estimated counts in at least 50% of the samples were included in downstream steps. After loading annotations and filtering by count, DTE models were generated in the *sleuth* package using a combination of the *sleuth_prep*, *sleuth_fit*, and *sleuth_lrt* functions. The *sleuth_prep* function initialized the *sleuth* object and read in the target mapping and bootstrap information from the provided annotation database and *wasabi*-processed data, respectively. The *sleuth_fit* function was then used to produce 2 smoothed linear models—“full” and “reduced.” In *sleuth*, the “full” model was fit using a smoothed linear model for experimental treatment (control vs dieldrin), whereas the “reduced” model was fit assuming equal abundances by treatment. Finally, the *sleuth_lrt* function uses a likelihood ratio test (LRT) to identify transcripts with a significantly improved fit in the “full” model. Differential transcript expression significance for the *sleuth* LRT was set to FDR < 0.05.

Figure 2. Reduced representation bisulfite sequencing (RRBS) and RNA-sequencing (RNA-seq) bioinformatics pipelines. RRBS and RNA-seq data were separately processed and analyzed using the indicated bioinformatics pipelines. The goal of the pipelines was to identify genome-wide changes in DNA methylation (RRBS) or transcript expression (RNA-seq) by developmental dieldrin exposure, and then generate lists of target genes. Linux command line tools and the open-source statistical software R (version 3.5.1) were used for all analyses.

For gene-level DTE follow-up at differentially methylated genes, significance was set at $p < .5$; results were considered marginally significant when $.5 < p < .1$.

Data visualization. Reduced representation bisulfite sequencing data were visualized using the *RnBeads* R package (version 2.0.0) (Assenov et al., 2014). First, the *rnb.execute.import* function was used to import the processed RRBS data. Next, the *rnb.sample.groups* function was used to order samples by treatment group. Finally, the *rnb.plot.locus.profile* function was used to plot DNA methylation values for specific regions of the genome (ie, identified DMCs or DMRs). For RNA-seq data, estimated counts extracted from *sleuth* were visualized using the *ggplot2* R package (version 3.1.0).

Pathway and network analysis. Gene ontology (GO) term enrichment testing and pathway analysis was performed on genes annotated to male and female DMCs using the ClueGO application in Cytoscape (version 3.6.1) (Bindea et al., 2009; Smoot et al., 2011). For ClueGO testing, hypo- and hypermethylated DMCs were input as separate marker lists, “groups” was selected as the visual style, and the gene ontology-biological process (GOBP) term was included for enrichment testing. Network specificity was set half-way between “Medium” and “Detailed,” such that the GO Tree Interval minimum was equal to 6 and the maximum was equal to 12. Only terms with at least 3 genes and a Bonferroni-corrected p -value $< .1$ were included in pathway visualizations. The connectivity score (Kappa) was set at 0.5, and default GO Term Grouping settings were used in all analyses. In addition to ClueGO analyses, gene-gene interaction network analysis was performed on genes annotated to male and female DMCs using STRING (version 10.5) (Szklarczyk et al., 2017). STRING network analysis was performed using default parameters, including a minimum required interaction score = 0.4 and all interaction sources activated.

RESULTS

Differential Methylation by Developmental Dieldrin Exposure

The *DSS* R package was used to identify DMCs from the RRBS data using a Bayesian hierarchical model based on the beta-binomial distribution. Due to the sex-specific phenotypic effects of dieldrin on neuronal susceptibility, we stratified differential methylation models by sex. Two-group Wald test models were used to test for differential DNA methylation by developmental dieldrin exposure (Figure 3A). In the female mice, we identified 478 DMCs (Supplementary Table 2). Comparing the directionality of the female DMCs, more DMCs were hypomethylated ($n = 321$; 67.2%) than hypermethylated ($n = 157$; 32.8%), suggesting a general pattern of decreased methylation with dieldrin exposure in female mice. Meanwhile, in the male mice, we identified 115 DMCs (Supplementary Table 3). Unlike the female data, more male DMCs were hypermethylated ($n = 74$; 64.3%) than hypomethylated ($n = 41$; 35.7%), indicating a pattern of hypermethylation in the male mice. Male and female DMCs showed no overlap between the 2 sexes (Figure 3C).

The *DSS* and *DMRcate* R packages were used to test for larger regions of differential methylation by dieldrin exposure (Figure 3A). In the female mice, we found 24 DMRs by dieldrin exposure (Supplementary Table 4). Meanwhile, in the male mice, we identified 14 DMRs by dieldrin exposure (Supplementary Table 5). In contrast to DMCs, for both the male and female mice, there was a slight skew toward hypermethylated DMRs (female $n = 15$; male $n = 9$) compared to hypomethylated DMRs (female $n = 9$; male $n = 5$). Consistent with our observations regarding the DMCs, the male and female DMRs showed no overlap between the 2 sexes (Figure 3C), showing sex-specific patterns of differential methylation on the regional scale.

The *annotatr* R package was used to annotate the detected DMCs and DMRs to known murine genes, regulatory features, enhancers, and miRNAs (Figure 3B). Differentially methylated

Figure 3. Dieldrin-related differential methylation identified from reduced representation bisulfite sequencing (RRBS) data. Using the *DSS* R package, 2-group Wald test models were used to test for differential DNA methylation by developmental dieldrin exposure in RRBS data from mouse midbrain samples collected at 12 weeks of age. Due to the sex-specific phenotypic effects of dieldrin on neuronal susceptibility, we stratified differential methylation models by sex. A, In female mice, we identified 478 differentially methylated CpGs (DMCs) by dieldrin exposure. More DMCs were hypomethylated ($n = 321$; 67.2%) than hypermethylated ($n = 157$; 32.8%), indicating a general pattern of decreased methylation with dieldrin exposure in female mice. Meanwhile, in the male mice, we identified 115 DMCs by dieldrin exposure. Unlike the female data, more of the male DMCs were hypermethylated ($n = 74$; 64.3%) than hypomethylated ($n = 41$; 35.7%), indicating a general pattern of hypermethylation in the male mice. B, DMCs and differentially methylated regions (DMRs) were annotated to genes using the *annotatr* R package. Not all identified DMCs and DMRs annotated to known gene regions. C, The bedtools intersect function was used to test for overlap between male and female DMCs/DMRs by chromosomal location. Male and female DMCs/DMRs showed no overlap between the 2 sexes.

CpGs and DMRs that annotated to any region or feature of a gene were considered “annotated” to that gene. In the female mice, the identified DMCs and DMRs annotated to 268 and 20 genes, respectively (Supplementary Tables 6 and 7). Meanwhile, in the male mice, the identified DMCs and DMRs annotated to 70 and 13 genes, respectively (Supplementary Tables 8 and 9). Reflecting the lack of overlap between DMCs and DMRs, we also observed no overlap between annotated genes. In addition, we characterized the functional annotation of the DMCs, annotating to known CpG categories (eg, CpG island), gene body locations (eg, exon), and regulatory features (eg, promoter). Both male and female DMCs showed similar genomic distributions, indicating that although specific patterns of dieldrin-induced differential methylation were sex-specific, the overall categories of features affected by exposure were not necessarily different by sex (Supplementary Figure 2).

ClueGO and STRING Pathway/Network Analyses for Developmental Exposure Model

Given that the DMCs annotated to a large number of genes, ClueGO was used to perform a GO enrichment analysis on the genes with dieldrin-induced differential methylation (Figure 4A). Input lists for ClueGO included all genes with annotated DMC or DMRs, regardless of DMC/DMR location. For the male DMCs, we

did not identify any significantly enriched GOBP terms after multiple testing correction. In contrast, for the female DMCs, we found a large number of significantly enriched GOBP terms, including cranial nerve development and central nervous system neuron development (Bonferroni-corrected p -value < .05) (Figure 4B). Most of the other enriched terms were also related to development, although in different biological systems (Supplementary Table 10). Next, the genes included in the significant GOBP terms (listed in Figure 4B) were extracted and placed into the STRING network interaction tool to investigate interactions between these genes (Figure 4C). We found that the genes from the significant female GOBP terms clustered together into a network. Of particular interest, 2 of the differentially methylated genes from the central nervous system neuron development pathway—*Nr4a2* and *Lmx1b*—are known to be critical for dopaminergic neuron development and maintenance.

Differential Methylation at Specific Genes of Interest From Developmental Exposure Model

To follow-up on the pathway and network analyses, the *RnBeads* R package was used to visualize DNA methylation levels at all differentially methylated genes in the central nervous system neuron development pathway. Although most of the genes showed minimal widespread differential methylation

Figure 4. ClueGO pathway analysis, significant terms/genes, and STRING interaction network. **A**, ClueGO was used to perform a gene ontology enrichment analysis on the genes with dieldrin-induced differential methylation. For the male differentially methylated CpGs (DMCs), we did not identify any significantly enriched gene ontology-biological process (GOBP) terms after correction for multiple testing. However, for the female DMCs, we found a large number of significantly enriched GOBP terms, including cranial nerve development and central nervous system neuron development (Bonferroni-corrected p -value $< .05$). **B**, Genes included in the significant GOBP terms were extracted. **C**, Genes from enriched GO terms were placed into the STRING network interaction tool to investigate interaction amongst these genes. We found that the genes from the significant female GOBP terms clustered together into a network. Two of the differentially methylated genes in the network—*Nr4a2* and *Lmx1b*—are known to be involved in dopaminergic neuron development. Six of the genes—*Heg1*, *Ano1*, *Edaradd*, *Hydin*, *Pkd2*, and *Tenm4*—showed no interactivity in the STRING network and were removed from the visualization.

across visualized gene bodies (Supplementary Figure 3), more pronounced changes in DNA methylation were apparent at the *Nr4a2* and *Lmx1b* genes, which have been implicated in dopaminergic neuron development and potentially PD (Dong et al., 2016; Doucet-Beaupré et al., 2016; Luo, 2012). Although only a single DMC was annotated to *Nr4a2*, when the entire gene body was visualized, there was a larger region of differential methylation that became apparent (Figure 5A). Similarly, in *Lmx1b*, we detected only a single DMC 1–5 kb upstream of the *Lmx1b* transcription start site using our statistical methods, but when visualized, there was consistent hypomethylation surrounding the detected DMC (Figure 5B). Fitting with the sex-specific genome-wide results, dieldrin-induced hypomethylation at *Nr4a2* (gene body) and *Lmx1b* was only present in the female mice. The inability of our selected analysis methods to detect these regions as DMRs was likely a result of the stringent cutoffs used by the DSS and DMRcate packages.

In addition to the genes that were identified from our pathway and network analyses, we also investigated potential differential methylation at *Pitx3*, one of the genes assessed in previous developmental dieldrin exposure data (Richardson et al., 2006). *Pitx3* is a transcription factor important for dopaminergic neuron development and maintenance that has also been implicated in PD (Li et al. 2009). Unlike *Lmx1b* and *Nr4a2*, however, there were no detected DMCs or DMRs annotated to *Pitx3*, and when visualized, the *Pitx3* gene body showed no apparent differential methylation on a regional scale (Figure 5C). However, it should be noted that RRBS data coverage across this gene region was poor apart from the CpG islands, a result that is likely due to the bias of the RRBS method toward CpG-dense regions of the genome.

Given that DMRs at imprinted genes have shown specific vulnerability to other developmental exposures (Marsit, 2015; Plasschaert and Bartolomei, 2014), we also investigated whether any of our identified dieldrin-related DMCs and DMRs annotated to imprinted loci. One of the identified female DMCs annotated to the promoter of the imprinted *Ascl2* locus, but none of the female DMRs annotated to an imprinted gene. Meanwhile, none of the identified male DMCs annotated to an imprinted gene, but 2 of the male-specific DMRs annotated to imprinted loci—*Grb10* and *Gnas*. When visualized, the *Gnas* DMR appeared to be a false positive driven by a low number of samples with data coverage (Supplementary Figure 4), but the *Grb10* DMR showed clear hypomethylation with dieldrin exposure in the male midbrain samples (Figure 5D). After annotation, we also found that this DMR overlaps a predicted mouse midbrain ENCODE enhancer region.

Whole-Genome DTE for Developmental Exposure Model

Using the sleuth R package, a LRT was used to test for differential gene expression (DGE) and DTE by dieldrin exposure. After filtering out transcripts with low estimated counts (< 10 in more than half of the samples), 56 608 and 55 623 transcripts were included for male and female differential models, respectively. After pooling gene transcripts into a single identifier for DGE models, zero genes showed significant differential expression (FDR < 0.10) by dieldrin exposure. Expanding the analysis to the transcript level, there were also zero transcripts with significant differential expression by dieldrin exposure (FDR < 0.10) in our genome-wide analyses for male (Supplementary Table 11) and female mice (Supplementary Table 12).

Target gene transcript-level analysis for developmental exposure model. Based on our differential methylation data, pathway analyses, and *a priori* hypotheses generated from previous

developmental dieldrin studies, we narrowed the scope of the DTE analysis to the following individual genes: *Nr4a2*, *Lmx1b*, *Grb10*, and *Pitx3*. At the *Nr4a2* gene, one of the protein-coding transcripts showed marginally significant increased expression in female midbrains by dieldrin exposure ($p = .06$) (Figure 6). This result was not seen in males ($p > .10$), which reflects the observed female-specific differential methylation detected within the *Nr4a2* gene body. These data partially corroborate findings from Richardson et al., who showed non-significant increases in *Nr4a2* with 0.3 mg/kg dieldrin in both male and female mice. However, these previous data were generated using primers that measure 2 protein-coding forms of *Nr4a2* simultaneously (Richardson et al., 2006), one of which is presented in Figure 6. As such, the female-specific marginal significance presented here may be driven by changes in a specific transcript that could not be detected in previous work. At the *Lmx1b* gene, one protein-coding transcript showed marginally significant decreased expression in male midbrains by dieldrin exposure ($p = .08$); this result was not apparent in the female mice ($p = .59$) (Figure 6). Meanwhile, at the *Grb10* gene, 2 protein-coding transcripts showed significant and marginally significant decreased expression in male midbrains by dieldrin exposure ($p = .05$ and $p = 0.06$, respectively) (Figure 6). In contrast, these same 2 transcripts showed significant dieldrin-related increases in expression in the female midbrains ($p < .05$). These results reinforce the idea that dieldrin has sex-specific effects on *Grb10* regulation. Finally, *Pitx3* did not show any DTE in male or female midbrains ($p > .1$) (Figure 6), a result that matches the lack of significant differential methylation at this locus. This lack of significant differential expression at the *Pitx3* locus was also consistent with findings from Richardson et al., who showed no change in *Pitx3* expression with 0.3 mg/kg dieldrin in males or females (Richardson et al., 2006). These previous data were generated using primers specific to the 1380 bp *Pitx3* protein-coding transcript (Richardson et al., 2006), the same transcript presented in Figure 6.

Differential Methylation in the Adult Dieldrin Exposure Model

Using the DSS R package, 2-group Wald test models were used to test for differential DNA methylation by adult dieldrin exposure in RRBS data generated from male midbrain samples collected at 12 weeks of age. In the adult exposure study, we identified 99 DMCs (Supplementary Table 13), of which 54 were hypermethylated and 45 were hypomethylated (Supplementary Figure 3). In addition to the DMCs, 9 DMRs were detected by adult dieldrin exposure (Supplementary Table 14). The identified DMCs and DMRs annotated to 79 and 4 unique genes, respectively (Supplementary Tables 15 and 16). None of the adult male exposure DMCs or DMRs overlapped with the developmental male exposure model results (Supplementary Figure 3).

Genes with annotated DMCs in the adult exposure model showed little enrichment for GOBP terms after correction for multiple testing. Specifically, only 1 GO term was enriched in the adult male DMCs—growth hormone secretion. These limited results make it difficult to interpret the biological significance of the adult exposure data. However, the available results do suggest that there are subtle epigenetic effects of dieldrin exposure in adult male mice that are distinct from the effects observed in the developmental exposure model.

DISCUSSION

Sex-Specific Epigenome-Wide Differential Methylation by Developmental Dieldrin Exposure

Previous animal work has shown that developmental dieldrin exposure has specific phenotypic effects in mice, including

Figure 5. Dieldrin-induced differential methylation at the *Nr4a2*, *Grb10*, *Lmx1b*, and *Pitx3* genes. DNA methylation was visualized at the *Nr4a2*, *Grb10*, *Lmx1b*, and *Pitx3* genes using the *RnBeads* R package. Differentially methylated CpGs (DMCs) and regions (DMRs) were detected using a combination of the *DSS* and *DMRcate* R packages. For all visualizations, the following features are shown from top to bottom: Ensembl gene cartoons, CpG islands (rectangular bars), and DNA methylation levels by individual sample in a dot plot with smoothed mean line. As indicated by labels, male data are shown on the left, whereas female data are shown on the right. Boxes with asterisks indicate areas of differential methylation detected in the *DSS* R package. A, A female-specific intronic DMC (chr2: 57110340, boxed) was identified within *Nr4a2*. The entire *Nr4a2* locus was visualized to show a larger region of apparent, but non-significant, dieldrin-induced hypermethylation surrounding the DMC. B, A female-specific, exonic DMC (boxed) was identified in the *Lmx1b* exon (chr2: 33644215). Additionally, a 700 bp region surrounding the identified *Lmx1b* DMC showed dieldrin-induced hypomethylation in the female mice. C, There was no significant differential methylation at covered CpG sites along the *Pitx3* locus; however, as shown in the plot, coverage across the *Pitx3* gene length was poor. Asterisks below boxes indicate significant differential methylation detected using the *DSS* package (DMC FDR < 0.05; DMR $p < .05$). D, A male-specific, intronic DMR (boxed) was identified at the imprinted *Grb10* locus (chr11: 12026498–12026597).

Figure 6. *Nr4a2*, *Grb10*, *Lmx1b*, and *Pitx3* RNA-seq transcript expression. Dot plots show RNA transcript expression for protein-coding *Nr4a2*, *Lmx1b*, *Pitx3*, and *Grb10* transcripts. Control and diel-drin-exposed mice for male and female mice are indicated on the left and right of each plot, respectively. Transcripts were annotated and assigned numbers using the Ensembl mouse transcriptome database (<https://useast.ensembl.org/index.html>; last accessed March 21, 2019). A likelihood ratio test was performed in the sleuth R package to determine significance of differential transcript expression. Significance is indicated by asterisks (*p-value ≤ .05).

disrupted expression of PD-related proteins, increased dopamine turnover, and increased susceptibility of dopaminergic neurons to the toxicant MPTP (Richardson et al., 2006). In that study, it was found that the lowest developmental diel-drin dose tested (0.3 mg/kg) induces these phenotypic effects despite no detectable diel-drin residues in offspring brain tissue (Richardson et al., 2006). Based on these results, we hypothesized that developmental diel-drin exposure induces changes in the epigenome that persist into adulthood. To test this hypothesis, we assessed whether developmental diel-drin exposure (0.3 mg/kg) is associated with changes in DNA methylation in adult mice.

Consistent with the sex-specific increase in susceptibility to MPTP (Richardson et al., 2006), we identified distinct patterns of differential methylation in male and female offspring at the individual cytosine level (Figure 3). This lack of overlap also extended to our pathway analysis for DMC gene annotations, where male mice showed no enrichment for GOBP terms and female mice showed enrichment for 9 GOBP terms (corrected p-value < .05) (Figure 4).

The lack of GO term enrichment makes it difficult to interpret the biological significance of the male-specific differential methylation. Although our data may indicate a reduced epigenetic response in males compared to females, it is possible that additional effects of diel-drin exposure on the male epigenome were simply not captured by the RRBS method, which is biased toward CpG-dense regions. It is also possible that areas of dynamic epigenetic regulation were “lost” during the annotation process, which remains largely limited to genic regions.

Alternatively, developmental diel-drin exposure may affect the dopaminergic system through chromatin modifications, an additional epigenetic mechanism. Histone acetylation is a chromatin modification that regulates transcriptional activity, and imbalances in this epigenetic mark have been implicated in neurodegeneration (Harrison and Dexter, 2013; Sharma and Taliyan, 2015). Furthermore, previous work has shown that diel-drin exposure can modify histone acetylation in rat dopaminergic neuronal cells, suggesting that this epigenetic mark may play a role in diel-drin neurotoxicity (Song et al., 2010). Future studies should utilize chromatin immunoprecipitation sequencing and whole-genome bisulfite sequencing (WGBS) to more comprehensively characterize the response of genome-wide histone acetylation and DNA methylation to developmental diel-drin exposure.

In contrast to the male data, the female DMCs annotated to genes enriched for a number of GO pathways, including central nervous system development and other developmental processes (Figure 4). Of the genes included in these enriched GOBP terms, one was previously examined in this model as a gene of interest (*Nr4a2*), and is known to be important for dopaminergic neuron development and maintenance (discussed below).

Our data add to a growing literature demonstrating the sex-specific nature of epigenetic responses to developmental exposures (Heijmans et al., 2008; Kippler et al., 2013; Kundakovic et al., 2013; Leung et al., 2018). Given that the male and female epigenomes can respond so differently to the environment, it is crucial that developmental exposure studies investigating epigenetic effects include both sexes.

Female-Specific Dieldrin-Related Differential Methylation at Genes Related to Dopaminergic Neuron Development

Using ClueGO pathway analysis, we found that the female DMCs were enriched at genes related to developmental processes, including central nervous development (Figure 4). Of particular interest, 2 of the genes included in the central nervous development GO term, *Nr4a2* and *Lmx1b*, are known to be critical for dopaminergic neuron maintenance and development (Doucet-Beaupré et al., 2016; Luo, 2012). *Nr4a2* encodes the nuclear receptor related-1 (Nurr1) protein. Nurr1 is a transcription factor involved in dopaminergic neuron development, and it has been suggested that dysregulation of the *Nr4a2* gene may contribute to the pathogenesis of PD (Decressac et al., 2013; Dong et al., 2016; Luo, 2012). Similarly, *Lmx1b* encodes LIM homeobox transcription factor 1 beta, a transcription factor involved in maintenance of cellular respiration in midbrain dopaminergic neurons (Doucet-Beaupré et al., 2016). *Lmx1b* inactivation has been shown to produce Parkinson's-like cellular features, including α -synuclein inclusions and progressive degeneration of dopaminergic neurons (Doucet-Beaupré et al., 2016). Furthermore, although little research has explored the role of human *LMX1B* in PD, some preliminary evidence suggests a positive association between 11 *LMX1B* polymorphisms and PD in human females (Bergman et al., 2009). Given the documented roles of *Nr4a2* and *Lmx1b* in the maintenance and development of dopaminergic neurons, altered regulation of the Nurr1 and *Lmx1b* transcription factors could influence susceptibility to dopaminergic toxicity. However, the female-specific epigenetic results presented here are difficult to reconcile with previous work showing a male-specific phenotype (Richardson et al., 2006). As such, further work must investigate the functional effects of these dieldrin-induced epigenetic effects in females.

In addition to *Nr4a2* and *Lmx1b*, previous work has also identified the related *Pitx3* locus as a potential risk factor for PD (Li et al., 2009). *Pitx3* encodes the pituitary homeobox 3 protein, a transcription factor that shows restricted, constitutive expression in the midbrain, where it is thought to play a role in development and maintenance of dopaminergic neurons (Li et al., 2009). Although some studies have shown associations between human *PITX3* polymorphisms and PD (Bergman et al., 2010; Fuchs et al., 2009; Haubenberger et al., 2011), findings have been inconsistent, and a recent meta-analysis suggested that the identified polymorphisms do not show significant associations with risk of PD (Jiménez-Jiménez et al., 2014). Reflecting this uncertainty, unlike the *Nr4a2* and *Lmx1b* genes, we did not identify dieldrin-related differential methylation at the *Pitx3* gene (Figure 5C). There were also no significant effects of developmental dieldrin exposure on *Pitx3* expression in male or female midbrains (Figure 6). These data match previous work showing no change in *Pitx3* expression after developmental exposure to 0.3 mg/kg dieldrin (Richardson et al., 2006), suggesting that *Pitx3* regulation is not altered by developmental dieldrin exposure.

Male-Specific Dieldrin-Related Differential Methylation at the Imprinted *Grb10* Locus

Imprinted genes, which display parent-of-origin-specific monoallelic expression, are regulated by DMRs and display particular sensitivity to developmental exposures (Marsit, 2015; Plasschaert and Bartolomei, 2014). Despite these characteristics, we did not identify widespread differential methylation at imprinted genes; however, we did find dieldrin-related hypomethylation in male mice at the imprinted *Grb10* locus (Figure 5B). Supporting the functional relevance of these epigenetic

findings, the identified *Grb10* DMR was annotated to a predicted mouse midbrain enhancer region, and 2 protein-coding *Grb10* transcripts demonstrated dieldrin-related changes in expression in the male midbrains (Figure 6). *Grb10* encodes growth-factor receptor bound protein 10 (Grb10), a signal adapter protein that regulates cellular proliferation, insulin signaling, and normal adult behavior (Dufresne and Smith, 2005; Plasschaert and Bartolomei, 2015). *Grb10* displays neuron-specific imprinting controlled by differential methylation at an imprinting control region (Plasschaert and Bartolomei, 2015), and the *Grb10* protein directly interacts with Grb10-interacting GYF Protein 2 (GIGYF2), a protein encoded within the *PARK11* locus (Giovannone et al., 2009). Previous work has shown that heterozygous *Gigyf2*^{+/-} mice develop adult-onset neurodegeneration (Giovannone et al., 2009), and meta-analyses of GIGYF2 genetic studies have suggested the protein may a role in PD-related neurodegeneration (Lautier et al., 2008; Zhang et al., 2015). As such, dieldrin-related changes in DNA methylation at *Grb10* have the potential to indirectly impact PD risk by regulating activity of GIGYF2. Future work should investigate whether dieldrin-induced differential methylation at *Grb10* has functional consequences for expression and/or function of *Grb10* and GIGYF2.

Poised Epigenetic State

Dieldrin-related epigenome-wide differential DNA methylation results were not reflected in genome-wide RNA-sequencing analysis, which completely lacked significance when corrected for multiple testing. Although seemingly contradictory, these data are consistent with the concept of “silent neurotoxicity” and suggest the possibility that developmental dieldrin exposure induces a poised methylome that is primed to respond to additional later-life exposures, but does not directly produce changes in phenotype. Such a model fits into the developmental origins of health and disease (DOHaD) paradigm, which holds that early-life environmental exposures modify disease risk into adulthood (Heindel and Vandenberg, 2015). Under this paradigm, the epigenome is a mechanism by which gene regulation is developmentally programmed to respond to later-life perturbations (Bianco-Miotto et al., 2017; Gluckman et al., 2008). When considering our results from a DOHaD perspective, it makes sense that a developmental exposure could produce genome-wide epigenetic changes without associated changes in gene expression. This work suggests that there is value in novel experimental paradigms that test whether developmental exposures alter sensitivity to toxic insults in adulthood.

Differences Between Adult and Developmental Exposures

In this study, there was no overlap between the DMCs and DMRs detected in the adult and developmental exposure models. Supporting these data, previous studies have shown that the developing brain is particularly sensitive to environmental perturbations (Rauh and Margolis, 2016; Rice and Barone, 2000), and that environmental chemicals can act as potent neurotoxins during development (Heyer and Meredith, 2017; Miodovnik, 2011). Furthermore, developmental exposures have the potential to modify epigenetic programming, which takes place during embryonic development (Feng et al., 2010; Marsit, 2015; Reik et al., 2001). These considerations, when combined with our data, suggest that timing of exposure is critical in determining the effects of dieldrin on the midbrain methylome, and that the neurotoxic response in the developing brain is distinct from the response in an adult brain.

Limitations

Although pathway and network analyses provided some context for our identified DMCs, the biological significance of dieldrin-related changes in epigenome-wide DNA methylation remains untested, and future studies will explore the functional relevance of these findings. Because existing GO databases only provide information on documented gene functions, it is quite possible that interpretation of our data is incomplete.

There are additional limitations that arise from the current technical limitations of epigenetic analyses performed in neuronal tissue. For one, our data are unable to address the issue of cell-type specificity of the observed changes. The amount of DNA required for bisulfite-based techniques, including RRBS, precludes a genome-wide analysis of methylation from enriched cell populations (ie, by fluorescence assisted cell sorting or laser capture microdissection). These enrichment techniques pair better with assessment of specific target genes and follow-up studies will explore the cell-type specificity of the observed changes in our identified differentially methylated genes.

In addition to high DNA requirements, the selected RRBS method also relies on bisulfite conversion, which cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine (5-hmC) (Huang et al., 2010). 5-hmC is a stable regulatory mark that is enriched in distal regulatory elements, exon-intron boundaries, and intragenic regions of transcriptionally active genes in neuronal tissue (Khare et al., 2012; Lister et al., 2013; Mellén et al., 2012; Wen et al., 2014). Given its genomic distribution and relative stability, intragenic 5-hmC may act as an activator of transcription in the brain (Hahn et al., 2014), and is thought to be particularly important in the etiology of neurological disorders (Al-Mahdawi et al., 2014; Cheng et al., 2015). Future studies could investigate whether our results are driven by changes in 5-hmC using paired bisulfite and oxidative-bisulfite treatments (Booth et al., 2013).

Additionally, the RRBS method is inherently biased toward CpG-dense regions, and only covered approximately 3 000 000 CpGs per sample. As a result, we may be missing out on additional dieldrin-related differential methylation in CpG-poor regions. This bias in the RRBS method is particularly concerning for the field of neuroepigenetics, where there is a growing recognition of the importance of DNA methylation along gene bodies, as well as in non-CpG dinucleotides (Guo et al., 2014; Lister et al., 2013). These issues could be addressed through the use of WGBS-Seq, the gold standard for measuring genome-wide DNA methylation; however, WGBS remains cost prohibitive.

Despite these limitations, which are typical for this field of research, to our knowledge, this is the first study to describe the effects of developmental dieldrin exposure on the mouse mid-brain methylome.

SUPPLEMENTARY DATA

Supplementary data are available at Toxicological Sciences online.

DECLARATION OF CONFLICTING INTERESTS

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ACKNOWLEDGMENTS

The authors thank Marie Adams at the Van Andel Genomics Core for providing consultation, library preparation (RNA-seq), and next-generation sequencing facilities and services (RRBS and RNA-seq). We also thank Claudia Lalancette at the University of Michigan Epigenomics Core for library preparation (RRBS) services.

FUNDING

This work was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under award (R21 ES029205, R00 ES024570 to A.I.B.).

REFERENCES

- Al-Mahdawi, S., Virmouni, S. A., and Pook, M. A. (2014). The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases. *Front. Neurosci.* **8**, 397.
- Allis, C. D., and Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. *Nat. Rev. Genet.* **17**, 487–500.
- Alter, S. P., Lenzi, G. M., Bernstein, A. I., and Miller, G. W. (2013). Vesicular integrity in Parkinson's disease. *Curr. Neurol. Neurosci. Rep.* **13**, 362.
- Andrews, S. (2016) FastQC: A quality control tool for high throughput sequence data. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>, last accessed March 22, 2019.
- Assenov, Y., Müller, F., Lutsik, P., Walter, J., Lengauer, T., and Bock, C. (2014). Comprehensive analysis of DNA methylation data with RnBeads. *Nat. Methods* **11**, 1138–1140.
- Bergman, O., Håkansson, A., Westberg, L., Belin, A. C., Sydow, O., Olson, L., Holmberg, B., Fratiglioni, L., Bäckman, L., Eriksson, E., et al. (2009). Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson's disease? *J. Neural. Transm.* **116**, 333–338.
- Bergman, O., Håkansson, A., Westberg, L., Nordenström, K., Carmine Belin, A., Sydow, O., Olson, L., Holmberg, B., Eriksson, E., Nissbrandt, H., et al. (2010). PITX3 polymorphism is associated with early onset Parkinson's disease. *Neurobiol. Aging* **31**, 114–117.
- Bianco-Miotto, T., Craig, J. M., Gasser, Y. P., van Dijk, S. J., and Ozanne, S. E. (2017). Epigenetics and DOHaD: From basics to birth and beyond. *J. Dev. Orig. Health Dis.* **8**, 513–519.
- Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., Galon, J., et al. (2009). ClueGO: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091–1093.
- Booth, M. J., Ost, T. W. B., Beraldi, D., Bell, N. M., Branco, M. R., Reik, W., and Balasubramanian, S. (2013). Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. *Nat. Protoc.* **8**, 1841–1851.
- Cannon, J. R., and Greenamyre, J. T. (2013). Gene-environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models. *Neurobiol. Dis.* **57**, 38–46.
- Caudle, W. M., Guillot, T. S., Lazo, C. R., and Miller, G. W. (2012). Industrial toxicants and Parkinson's disease. *Neurotoxicology* **33**, 178–188.
- Cavalcante, R. G., and Sartor, M. A. (2017). annotatr: Genomic regions in context. *Bioinformatics* **33**, 2381–2383.
- CDC (2016). Biomonitoring summary—Organochlorine pesticides overview. *Centers Dis. Control Prev. Natl. Biomonitoring*

- Progr. https://www.cdc.gov/biomonitoring/Trichlorophenols_BiomonitoringSummary.html, last accessed March 22, 2019.
- Cheng, Y., Bernstein, A., Chen, D., and Jin, P. (2015). 5-Hydroxymethylcytosine: A new player in brain disorders? *Exp. Neurol.* **268**, 3–9.
- Cicchetti, F., Drouin-Ouellet, J., and Gross, R. E. (2009). Environmental toxins and Parkinson's disease: What have we learned from pesticide-induced animal models? *Trends Pharmacol. Sci.* **30**, 475–483.
- Corrigan, F. M., Wienburg, C. L., Shore, R. F., Daniel, S. E., and Mann, D. (2000). Organochlorine insecticides in substantia nigra in Parkinson's disease. *J. Toxicol. Environ. Health A* **59**, 229–234.
- Decressac, M., Volakakis, N., Björklund, A., and Perlmann, T. (2013). NURR1 in Parkinson disease—From pathogenesis to therapeutic potential. *Nat. Rev. Neurol.* **9**, 629–636.
- Dong, J., Li, S., Mo, J.-L., Cai, H.-B., and Le, W.-D. (2016). Nurr1-based therapies for Parkinson's disease. *CNS Neurosci. Ther.* **22**, 351–359.
- Dufresne, A. M., and Smith, R. J. (2005). The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. *Endocrinology* **146**, 4399–4409.
- Doucet-Beaupré, H., Gilbert, C., Profes, M. S., Chabrat, A., Pacelli, C., Giguère, N., Rioux, V., Charest, J., Deng, Q., Laguna, A., et al. (2016). Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E4387–E4396.
- Fahn, S. (2003). Description of Parkinson's disease as a clinical syndrome. *Ann. N. Y. Acad. Sci.* **991**, 1–14.
- Faulk, C., and Dolinoy, D. C. (2011). Timing is everything: The when and how of environmentally induced changes in the epigenome of animals. *Epigenetics* **6**, 791–797.
- Feng, H., Conneely, K. N., and Wu, H. (2014). A Bayesian hierarchical model to detect differentially methylated loci from single nucleotide resolution sequencing data. *Nucleic Acids Res.* **42**, 1–11.
- Feng, S., Jacobsen, S. E., and Reik, W. (2010). Epigenetic reprogramming in plant and animal development. *Science* **330**, 622–627.
- Fleming, S. M. (2017). Mechanisms of gene-environment interactions in Parkinson's disease. *Curr. Environ. Heal. Rep.* **4**, 192–199.
- Freire, C., and Koifman, S. (2012). Pesticide exposure and Parkinson's disease: Epidemiological evidence of association. *Neurotoxicology* **33**, 947–971.
- Fuchs, J., Mueller, J. C., Lichtner, P., Schulte, C., Munz, M., Berg, D., Wüllner, U., Illig, T., Sharma, M., Gasser, T., et al. (2009). The transcription factor PITX3 is associated with sporadic Parkinson's disease. *Neurobiol. Aging* **30**, 731–738.
- Giovannone, B., Tsiaras, W. G., de la Monte, S., Klysik, J., Lautier, C., Karashchuk, G., Goldwurm, S., and Smith, R. J. (2009). GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. *Hum. Mol. Genet.* **18**, 4629–4639.
- Gluckman, P. D., Hanson, M. A., Cooper, C., and Thornburg, K. L. (2008). Effect of in utero and early-life conditions on adult health and disease. *N. Engl. J. Med.* **359**, 61–73.
- Goldman, S. M., Musgrove, R. E., Jewell, S. A., and Di Monte, D. A. (2017). Pesticides and Parkinson's disease: Current experimental and epidemiological. *Adv. Neurotoxicol.* **1**, 83–117.
- Gonzales, C., Zaleska, M. M., Riddell, D. R., Atchison, K. P., Robshaw, A., Zhou, H., and Sukoff Rizzo, S. J. (2014). Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice. *Pharmacol. Biochem. Behav.* **126**, 28–35.
- Gu, H., Bock, C., Mikkelsen, T. S., Jäger, N., Smith, Z. D., Tomazou, E., Gnirke, A., Lander, E. S., and Meissner, A. (2010). Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. *Nat. Methods* **7**, 133–136.
- Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., Zhong, C., Hu, S., Le, T., Fan, G., et al. (2014). Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. *Nat. Neurosci.* **17**, 215–222.
- Hahn, M. A., Szabó, P. E., and Pfeifer, G. P. (2014). 5-Hydroxymethylcytosine: A stable or transient DNA modification? *Genomics* **104**, 314–323.
- Harrison, I. F., and Dexter, D. T. (2013). Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease? *Pharmacol. Ther.* **140**, 34–52.
- Hatcher, J. M., Richardson, J. R., Guillot, T. S., McCormack, A. L., Di Monte, D. A., Jones, D. P., Pennell, K. D., and Miller, G. W. (2007). Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. *Exp. Neurol.* **204**, 619–630.
- Haubenberger, D., Reinthaler, E., Mueller, J. C., Pirker, W., Katzenschlager, R., Froehlich, R., Bruecke, T., Daniel, G., Auff, E., Zimprich, A., et al. (2011). Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. *Neurobiol. Aging* **32**, 302–307.
- Heijmans, B. T., Tobi, E. W., Stein, A. D., Putter, H., Blauw, G. J., Susser, E. S., Slagboom, P. E., and Lumey, L. H. (2008). Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 17046–17049.
- Heindel, J. J., and Vandenberg, L. N. (2015). Developmental origins of health and disease: A paradigm for understanding disease cause and prevention. *Curr. Opin. Pediatr.* **27**, 248–253.
- Heyer, D. B., and Meredith, R. M. (2017). Environmental toxicology: Sensitive periods of development and neurodevelopmental disorders. *Neurotoxicology* **58**, 23–41.
- Huang, Y., Pastor, W. A., Shen, Y., Tahiliani, M., Liu, D. R., and Rao, A. (2010). The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. *PLoS One* **5**, e8888.
- Jakovcevski, M., and Akbarian, S. (2012). Epigenetic mechanisms in neurological disease. *Nat. Med.* **18**, 1194–1204.
- Jiménez-Jiménez, F. J., García-Martín, E., Alonso-Navarro, H., and Agúndez, J. A. G. (2014). PITX3 and risk for Parkinson's disease: A systematic review and meta-analysis. *Eur. Neurol.* **71**, 49–56.
- Jorgenson, J. L. (2001). Aldrin and dieldrin: A review of research on their production, environmental deposition and fate, bioaccumulation, toxicology, and epidemiology in the United States. *Environ. Health Perspect.* **109**, 113–139.
- Kanthasamy, A. G., Kitazawa, M., Kanthasamy, A., and Anantharam, V. (2005). Dieldrin-induced neurotoxicity: Relevance to Parkinson's disease pathogenesis. *Neurotoxicology* **26**, 701–719.
- Khare, T., Pai, S., Koncivicius, K., Pal, M., Kriukiene, E., Liutkeviciute, Z., Irimia, M., Jia, P., Ptak, C., Xia, M., et al. (2012). 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. *Nat. Struct. Mol. Biol.* **19**, 1037–1043.
- Kippler, M., Engström, K., Mlakar, S. J., Bottai, M., Ahmed, S., Hossain, M. B., Raqib, R., Vahter, M., and Broberg, K. (2013). Sex-specific effects of early life cadmium exposure on DNA methylation and implications for birth weight. *Epigenetics* **8**, 494–503.

- Kochmanski, J., VanOeveren, S. E., and Bernstein, A. I. (2019). Data from: Developmental dieldrin exposure alters DNA methylation at genes related to dopaminergic neuron development and Parkinson's disease in mouse midbrain. *Toxicol. Sci.* **169**, 593–607. doi: 10.5061/dryad.s3n76mr
- Krueger, F. (2017) Trim Galore: A wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files, with some extra functionality for MspI-digested RRBS-type (reduced representation bisulfite-seq) libraries. https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/, last accessed March 21, 2019.
- Krueger, F. (2018) Bismark: A tool to map bisulfite converted sequence reads and determine cytosine methylation states. <https://www.bioinformatics.babraham.ac.uk/projects/bismark/>, last accessed March 21, 2019.
- Kundakovic, M., Gudsnuik, K., Franks, B., Madrid, J., Miller, R. L., Perera, F. P., and Champagne, F. A. (2013). Sex-specific epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 9956–9961.
- Labbé, C., Lorenzo-Betancor, O., and Ross, O. A. (2016). Epigenetic regulation in Parkinson's disease. *Acta Neuropathol.* **132**, 515–530.
- Langmead, B. (2017) Bowtie 2: Fast and sensitive read alignment. <http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>, last accessed March 21, 2019.
- Lardenoije, R., Pishva, E., Lunnon, K., and van den Hove, D. L. (2018) Neuroepigenetics of aging and age-related neurodegenerative disorders. *Prog. Mol. Biol. Transl. Sci.* **158**, 49–82.
- Lautier, C., Goldwurm, S., Dürr, A., Giovannone, B., Tsiaras, W. G., Pezzoli, G., Brice, A., and Smith, R. J. (2008). Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. *Am. J. Hum. Genet.* **82**, 822–833.
- Leung, Y.-K., Ouyang, B., Niu, L., Xie, C., Ying, J., Medvedovic, M., Chen, A., Weihe, P., Valvi, D., Grandjean, P., et al. (2018). Identification of sex-specific DNA methylation changes driven by specific chemicals in cord blood in a Faroese birth cohort. *Epigenetics* **13**, 290–300.
- Li, J., Dani, J. A., and Le, W. (2009). The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease. *Curr. Top. Med. Chem.* **9**, 855–859.
- Lill, C. M. (2016). Genetics of Parkinson's disease. *Mol. Cell. Probes* **30**, 386–396.
- Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., Lucero, J., Huang, Y., Dwork, A. J., Schultz, M. D., et al. (2013). Global epigenomic reconfiguration during mammalian brain development. *Science* **341**, 1237905.
- Luo, Y. (2012). The function and mechanisms of Nurr1 action in midbrain dopaminergic neurons, from development and maintenance to survival. *Int. Rev. Neurobiol.* **102**, 1–22.
- Marques, S., and Outeiro, T. F. (2013) Epigenetics in Parkinson's and Alzheimer's diseases. *Subcell. Biochem.* **61**, 507–525.
- Marsit, C. J. (2015). Influence of environmental exposure on human epigenetic regulation. *J. Exp. Biol.* **218**, 71–79.
- Mellén, M., Ayata, P., Dewell, S., Kriaucionis, S., and Heintz, N. (2012). MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. *Cell* **151**, 1417–1430.
- Miller, G. W., Gainetdinov, R. R., Levey, A. I., and Caron, M. G. (1999). Dopamine transporters and neuronal injury. *Trends Pharmacol. Sci.* **20**, 424–429.
- Miodovnik, A. (2011). Environmental neurotoxicants and developing brain. *Mt Sinai J. Med.* **78**, 58–77.
- Miranda-Morales, E., Meier, K., Sandoval-Carrillo, A., Salas-Pacheco, J., Vázquez-Cárdenas, P., and Arias-Carrión, O. (2017). Implications of DNA methylation in Parkinson's disease. *Front. Mol. Neurosci.* **10**, 225.
- Moretto, A., and Colosio, C. (2011). Biochemical and toxicological evidence of neurological effects of pesticides: The example of Parkinson's disease. *Neurotoxicology* **32**, 383–391.
- Patro, R. (2018) wasabi: Prepare Sailfish and Salmon output for downstream analysis. <https://github.com/COMBINE-lab/wasabi>, last accessed March 21, 2019.
- Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419.
- Peters, T. J., Buckley, M. J., Statham, A. L., Pidsley, R., Samaras, K., V Lord, R., Clark, S. J., and Molloy, P. L. (2015). De novo identification of differentially methylated regions in the human genome. *Epigenetics Chromatin* **8**, 6.
- Pimentel, H., Bray, N. L., Puente, S., Melsted, P., and Pachter, L. (2017). Differential analysis of RNA-seq incorporating quantification uncertainty. *Nat. Methods* **14**, 687–690.
- Plasschaert, R. N., and Bartolomei, M. S. (2014). Genomic imprinting in development, growth, behavior and stem cells. *Development* **141**, 1805–1813.
- Plasschaert, R. N., and Bartolomei, M. S. (2015). Tissue-specific regulation and function of Grb10 during growth and neuronal commitment. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 6841–6847.
- Quinlan, A. R., and Kindlon, N. (2017) bedtools: A powerful toolset for genome arithmetic. <https://bedtools.readthedocs.io/en/latest/>, last accessed March 21, 2019.
- Rauh, V. A., and Margolis, A. E. (2016). Research review: Environmental exposures, neurodevelopment, and child mental health—New paradigms for the study of brain and behavioral effects. *J. Child Psychol. Psychiatr.* **57**, 775–793.
- Reik, W., Dean W., and Walter, J. (2001). Epigenetic reprogramming in mammalian development. *Science*, **293**, 1089–1093.
- Rice, D., and Barone, S. (2000). Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. *Environ. Health Perspect.* **108**, 511–533.
- Richardson, J. R., Caudle, W. M., Wang, M., Dean, E. D., Pennell, K. D., and Miller, G. W. (2006). Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. *FASEB J* **20**, 1695–1697.
- Salvatore, M. F., Pruett, B. S., Dempsey, C., and Fields, V. (2012). Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area. *J. Vis. Exp.* **66**, 4171.
- Sharma, S., and Taliyan, R. (2015). Targeting histone deacetylases: A novel approach in Parkinson's disease. *Parkinson's Dis* **2015**, 1–11.
- Smoot, M. E., Ono, K., Ruscchinski, J., Wang, P.-L., and Ideker, T. (2011). Cytoscape 2.8: New features for data integration and network visualization. *Bioinformatics* **27**, 431–432.
- Song, C., Kanthasamy, A., Anantharam, V., Sun, F., and Kanthasamy, A. G. (2010). Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: Relevance to epigenetic mechanisms of neurodegeneration. *Mol. Pharmacol.* **77**, 621–632.
- Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017). The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* **45**, D362–D368.
- Trinh, J., and Farrer, M. (2013). Advances in the genetics of Parkinson disease. *Nat. Rev. Neurol.* **9**, 445–454.

- Uhl, G. R. (1998). Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. *Ann. Neurol.* **43**, 555–560.
- Wang, Z., Gerstein, M., and Snyder, M. (2009). RNA-Seq: A revolutionary tool for transcriptomics. *Nat. Rev. Genet.* **10**, 57–63.
- Wen, L., Li, X., Yan, L., Tan, Y., Li, R., Zhao, Y., Wang, Y., Xie, J., Zhang, Y., Song, C., et al. (2014). Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. *Genome Biol.* **15**, R49.
- Wüllner, U., Kaut, O., deBoni, L., Piston, D., and Schmitt, I. (2016). DNA methylation in Parkinson's disease. *J. Neurochem.* **139**, 108–120.
- Zhang, Y., Sun, Q.-Y., Yu, R.-H., Guo, J.-F., Tang, B.-S., and Yan, X.-X. (2015). The contribution of GIGYF2 to Parkinson's disease: A meta-analysis. *Neurol. Sci.* **36**, 2073–2079.